Health Recovery Solutions (HRS), a remote patient monitoring company based in Hoboken, New Jersey, said on 3 March 2026 that it had acquired Rimidi, an Atlanta-based company that builds chronic disease management and remote monitoring software with its roots in diabetes and cardiometabolic care.
Neither company disclosed the price or other financial terms, and no deal value appeared in trade coverage of the announcement. HRS is a portfolio company of growth investor LLR Partners, which republished the announcement on its own website.
Rimidi's founder and chief executive, Dr. Lucienne Ide, joined HRS as its chief medical officer. HRS said the integration of the two businesses would continue through the year and that dedicated support teams had been set up to avoid disrupting patient care programmes that customers already run.
What Rimidi built
Rimidi sells software, services and connected devices to healthcare providers, and its software is built into electronic health record (EHR) systems. The platform combines data from the health record, readings from patients' devices and patient survey answers so that clinicians can follow care guidelines and pick out the patients who need attention most.
One of its main features is the collection of continuous glucose monitoring (CGM) data from Dexcom, Libre and Eversense devices inside the EHR workflow, so doctors do not have to log into separate device portals. According to HRS, one of Rimidi's healthcare partners recorded an average 2.8% reduction in hemoglobin A1c, a standard measure of blood sugar control, and fewer hospital stays among high-risk patients with type 2 diabetes.
In 2018, HIT Consultant described the company as offering separate modules for diabetes and heart failure, with the heart failure product designed to help practices monitor patients and reduce avoidable admissions.
“HRS’s leadership in enterprise remote patient care and dedication to quality perfectly complement the mission Rimidi was founded on.”
Why HRS is buying
HRS has worked in remote patient monitoring for more than a decade and says its programmes have served more than one million patients for hundreds of healthcare organisations in North America. Its main product is the PatientConnect platform. In 2025 it introduced PatientFirst Pathways, a longitudinal care model, and in 2026 it became a full provider of Chronic Care Management services.
The company said the deal addressed three problems its customers face: running remote monitoring at scale across several conditions, building longer-term care models, and cutting the number of vendors they have to manage. HRS customers will be able to buy Rimidi's diabetes management and CGM integration through a single partner, which the companies said would simplify buying, training and support.
HRS chief executive Jason Comer tied the purchase to the company's recent product launches, saying the deal improved its ability to deliver longitudinal care and pointing to Rimidi's clinical workflow experience and record in diabetes management.
The founder and the funding
Rimidi was founded in Atlanta in 2012, according to HIT Consultant, and was previously known as Rimidi Diabetes. Ide, a physician, founded the company. In 2018 HIT Consultant reported that business executive Josh Claman was chief executive; by the time of the sale, Ide held the CEO title again.
In July 2018 Rimidi raised $6.575 million in a Series A-1 round that included a strategic investment from Eli Lilly and Company and money from Turner Investments, alongside existing investors Cox Enterprises, Village Capital, The Jump Fund and JAMB Global. Rimidi did not disclose its total funding or headcount at the time of the sale.
In the HRS announcement, Ide said that combining Rimidi's experience in ambulatory disease management with the HRS platform would let the two teams support patients across care settings, conditions and levels of acuity.
What happens to customers
Existing HRS customers gain diabetes and clinical management tools that sit alongside PatientConnect. Rimidi customers gain access to HRS's wider remote care offering, including its post-acute care experience and device logistics.
The companies did not say whether the Rimidi brand would be kept or when the products would be fully combined, beyond saying that integration work would run through 2026.
